Lacto-N-triose II alleviates metabolic dysfunction-associated Steatotic liver disease via microbiota-dependent citrulline biosynthesis
Authors:
- 15 January 2026
- journal article
- Published by Elsevier in Food Research International
- Vol. 228, 118448
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82470615)
This publication has 31 references indexed in Scilit:
- 3-Fucosyllactose Prevents Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota-Derived Pantothenate in MiceJournal of Agricultural and Food Chemistry, 2025
- Steatotic liver diseaseThe Lancet, 2024
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLDCurrent Obesity Reports, 2024
- Agile scores in MASLD and ALD: External validation and their utility in clinical algorithmsJournal of Hepatology, 2024
- Human milk oligosaccharides as prebioticsPediatrics & Neonatology, 2023
- Gut Parabacteroides merdae protects against cardiovascular damage by enhancing branched-chain amino acid catabolismNature Metabolism, 2022
- Production of HMOs using microbial hosts — from cell engineering to large scale productionCurrent Opinion in Biotechnology, 2019
- Parabacteroides distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile AcidsCell Reports, 2019
- Human milk and related oligosaccharides as prebioticsCurrent Opinion in Biotechnology, 2013
- Citrulline: From metabolism to therapeutic useNutrition, 2013